1. [CASE 1 — QUESTION 1] A 34-year-old man is brought to the emergency department by ambulance after his partner found him unresponsive at home. An empty blister pack of amitriptyline 150 mg tablets (30 tablets) is found at the scene. On arrival he is deeply somnolent but responds to sternal rub. Vital signs: heart rate 126 bpm, blood pressure 88/52 mmHg, respiratory rate 14 per minute, temperature 37.2°C. His skin is dry and flushed, his pupils are dilated at 7 mm bilaterally, and his bladder is palpable above the pubic symphysis. A 12-lead ECG is obtained immediately. The QRS duration is 108 ms with a rightward terminal axis deviation and a prominent R wave measuring 4 mm in lead aVR. An intravenous line is placed and continuous cardiac monitoring is initiated. Which of the following correctly identifies the mechanism responsible for the ECG findings and explains why this patient requires immediate pharmacological intervention rather than observation?

• A) The QRS widening reflects hyperkalemia-induced membrane depolarization from amitriptyline-induced renal tubular acidosis; the rightward axis shift indicates right bundle branch block from a cardiac contusion sustained during the fall; intervention is indicated only if potassium exceeds 6.5 mEq/L
• B) The QRS widening and rightward terminal axis shift reflect amitriptyline blockade of fast cardiac sodium channels (Nav1.5), slowing phase 0 depolarization of the cardiac action potential; a QRS exceeding 100 ms predicts seizure risk and a prominent R wave in lead aVR greater than 3 mm independently predicts both seizures and ventricular arrhythmia; both thresholds have been crossed and immediate sodium bicarbonate therapy is indicated without waiting for arrhythmia to develop
• C) The QRS widening reflects prolonged QT interval misidentified as QRS broadening on the bedside monitor; the correct management is intravenous magnesium sulfate to prevent torsades de pointes; the aVR finding is a normal variant and does not require treatment
• D) The QRS widening and axis shift reflect sinus tachycardia with rate-related aberrant conduction through the right bundle; because the QRS is only 108 ms and aberrancy at heart rate 126 bpm is physiological, no specific cardiac intervention is indicated and the ECG will normalize when the heart rate falls
• E) The ECG changes reflect amitriptyline-induced alpha-1 adrenergic blockade causing reflex tachycardia with rate-dependent QRS widening; intervention should target the tachycardia with a short-acting beta-blocker, which will narrow the QRS by reducing the heart rate and restoring normal intraventricular conduction

2. [CASE 1 — QUESTION 2] Continuing with the same patient. Sodium bicarbonate 100 mEq is administered intravenously over five minutes. A repeat ECG ten minutes later shows QRS narrowing to 96 ms and the blood pressure has improved to 98/62 mmHg. The senior resident asks the intern to explain the two distinct pharmacological mechanisms by which sodium bicarbonate produced this improvement, and specifically why the alkalinization component works at the molecular level. The intern also needs to explain why a nephrology fellow's concurrent suggestion to add urinary alkalinization with acetazolamide to enhance renal TCA excretion should be declined. Which of the following correctly addresses all three points?

• A) First mechanism: alkalinization increases the ionized (cationic) form of amitriptyline in blood, which binds the sodium channel more tightly and paradoxically stabilizes channel conductance; second mechanism: bicarbonate anion directly displaces amitriptyline from the Nav1.5 binding site through competitive anionic substitution; urinary alkalinization declined because acetazolamide causes metabolic acidosis that would counteract systemic alkalinization
• B) First mechanism: alkalinization to pH 7.45--7.55 activates endogenous sodium channel repair enzymes in cardiac myocytes that remove the TCA from the binding site; second mechanism: the sodium load stimulates aldosterone release, which increases cardiac sodium channel expression; urinary alkalinization declined because acetazolamide inhibits CYP2D6 and would raise amitriptyline levels further
• C) First mechanism: alkalinization shifts amitriptyline from its ionized cationic form toward the unionized free-base form, which has substantially lower binding affinity for the intracellular Nav1.5 receptor site, directly reducing sodium channel blockade; second mechanism: the sodium load delivered by the bicarbonate solution increases the electrochemical gradient driving sodium into myocytes during phase 0, partially compensating for reduced channel availability; urinary alkalinization with acetazolamide declined because amitriptyline's volume of distribution of 10 to 50 L/kg means only a negligible fraction of total body drug resides in plasma -- even maximal renal excretion of plasma-derived drug removes a pharmacologically insignificant portion of total body burden
• D) First mechanism: alkalinization to pH 7.45--7.55 shifts amitriptyline from its ionized cationic form -- which has higher Nav1.5 binding affinity -- toward the unionized free-base form with lower channel affinity, directly reducing channel blockade; second mechanism: the sodium load in the bicarbonate solution increases the inward electrochemical driving force for sodium across the myocyte membrane, partially compensating for blocked channels even when some remain inhibited; urinary alkalinization declined because amitriptyline's enormous volume of distribution (10 to 50 L/kg) means the plasma fraction is negligible -- even perfect renal clearance of plasma removes an insignificant fraction of total body drug sequestered in tissues
• E) First mechanism: bicarbonate neutralizes the lactic acid produced by TCA-induced cardiovascular compromise, restoring normal pH and allowing intrinsic cardiac conduction to recover; second mechanism: bicarbonate competes with amitriptyline for protein binding sites on alpha-1-acid glycoprotein, freeing binding capacity and reducing the free TCA fraction; urinary alkalinization declined because acetazolamide is a diuretic that would cause hypovolemia and worsen the hypotension

3. [CASE 1 — QUESTION 3] Continuing with the same patient. Forty minutes after admission, despite the initial bicarbonate therapy and ongoing resuscitation, the patient develops a generalized tonic-clonic seizure lasting 75 seconds. His current QRS is 104 ms. A nurse asks for an anticonvulsant order. A new intern, responding to the seizure, reaches for the phenytoin protocol used on the general neurology ward. The attending physician intervenes, instructs the intern not to give phenytoin, and orders a different agent. Which of the following correctly identifies the appropriate first-line anticonvulsant, explains why it is preferred in this setting, and provides the specific mechanistic reason phenytoin must not be given to this patient?

• A) Lorazepam administered intravenously is the first-line anticonvulsant for TCA-associated seizures; it enhances GABAergic inhibitory conductance at GABA-A receptors, raising seizure threshold without any effect on cardiac conduction; phenytoin must not be given because its primary anticonvulsant mechanism operates through sodium channel blockade -- and adding sodium channel blockade to a myocardium with TCA-induced sodium channel toxicity and QRS widening of 104 ms is directly additive, with real risk of worsening conduction impairment and precipitating ventricular arrhythmia
• B) Phenobarbital intravenously is the first-line agent because it has both GABAergic and sodium channel-blocking properties, the latter of which counteracts the TCA-induced depolarization block in the CNS that is driving seizure activity; phenytoin should be avoided only because it causes hypotension in the setting of already-low blood pressure, not because of any cardiac conduction interaction
• C) Levetiracetam intravenously is the first-line agent because it has no effect on cardiac sodium channels and no hemodynamic effects; phenytoin is avoided because it competitively inhibits CYP2D6, which would raise amitriptyline plasma concentrations by reducing its metabolic clearance and worsening toxicity
• D) Valproate intravenously is the first-line agent because it blocks sodium channels and GABA transaminase simultaneously, addressing both the sodium channel excess in the CNS and the GABAergic deficit; phenytoin is avoided because it irreversibly inhibits cardiac MAO-B, converting the TCA overdose presentation into a combined TCA-MAOI toxidrome
• E) Magnesium sulfate intravenously is the first-line anticonvulsant because TCA-induced seizures are driven by NMDA receptor activation from glutamate excitotoxicity, and magnesium blocks NMDA channels by voltage-dependent pore occlusion; phenytoin is acceptable after magnesium has been given because magnesium pre-treatment reduces the sodium channel binding capacity available for phenytoin

4. [CASE 1 — QUESTION 4] Continuing with the same patient. The seizure terminates after lorazepam. The patient is now intubated and mechanically ventilated. His QRS has narrowed to 98 ms with ongoing bicarbonate therapy maintaining blood pH 7.50. A psychiatry consultant reviewing the case notes that despite the clinical improvement, the patient still shows signs of persistent anticholinergic toxicity -- dilated pupils, absent bowel sounds, and bladder distension requiring catheterization. The consultant suggests intravenous physostigmine to reverse the anticholinergic syndrome and a nephrology colleague suggests initiating hemodialysis to accelerate amitriptyline removal now that the patient is stabilized. Which of the following correctly evaluates both suggestions?

• A) Both suggestions should be accepted; physostigmine is safe once the QRS has narrowed below 100 ms because the cardiac sodium channel blockade is sufficiently reversed; hemodialysis is effective for amitriptyline removal because the drug has been redistributed from tissues to plasma during the bicarbonate-induced pH shift and is now available for dialytic clearance
• B) Physostigmine should be accepted and hemodialysis declined; physostigmine's central anticholinergic reversal will reduce the need for ongoing sedation and facilitate weaning from mechanical ventilation; hemodialysis is declined because the dialysis circuit requires heparin anticoagulation, which carries bleeding risk in this patient
• C) Both suggestions should be declined; physostigmine is contraindicated because amitriptyline irreversibly inactivates acetylcholinesterase, making any cholinesterase inhibitor ineffective; hemodialysis is ineffective because the dialysis membrane pore size excludes amitriptyline's large molecular weight of approximately 2,800 daltons
• D) Physostigmine should be declined and hemodialysis accepted; hemodialysis is highly effective for amitriptyline because systemic alkalinization has shifted amitriptyline from tissue-bound to plasma-free form, making it accessible to dialytic clearance; physostigmine is declined because its half-life of only 20 minutes makes it impractical for sustained anticholinergic reversal
• E) Both suggestions should be declined; physostigmine is contraindicated in TCA overdose with cardiac toxicity because its cholinesterase inhibition increases acetylcholine at the sinoatrial node and cardiac conduction system, enhancing vagal tone and risking bradycardia or asystole in a myocardium with residual sodium channel compromise; hemodialysis is not effective for amitriptyline removal because the drug's enormous volume of distribution (10 to 50 L/kg) means only a negligible fraction of total body drug resides in plasma -- the tissue reservoir is too large for extracorporeal plasma clearance to meaningfully reduce total body burden

5. [CASE 2 — QUESTION 1] A 58-year-old woman with recurrent major depressive disorder and diabetic peripheral neuropathy has been managed on amitriptyline for both indications for three years. Her current dose is 100 mg nightly. At her routine follow-up, a plasma drug level is drawn and the laboratory reports two compounds: amitriptyline 138 ng/mL and a second compound at 91 ng/mL, for a combined value of 229 ng/mL. Her psychiatrist explains that this dual-compound result is expected and pharmacologically informative. Which of the following correctly identifies the second compound, the enzymatic reaction that produces it, and the clinical reason that monitoring both compounds is necessary rather than measuring amitriptyline alone?

• A) The second compound is clomipramine, produced by ring hydroxylation of amitriptyline's tricyclic nucleus by CYP1A2; monitoring both is necessary because clomipramine has much higher serotonin transporter inhibitory potency than amitriptyline and its level drives SERT-dependent antidepressant efficacy independently of the parent drug level
• B) The second compound is amitriptyline N-oxide, produced by CYP3A4-mediated N-oxidation of the tertiary amine nitrogen; monitoring both is necessary because N-oxide accumulation at high combined concentrations selectively inhibits cardiac potassium channels and predicts QTc prolongation risk independently of the parent drug sodium channel effects
• C) The second compound is nortriptyline, produced by CYP2D6-mediated N-demethylation of amitriptyline's tertiary amine to a secondary amine; nortriptyline is pharmacologically active and contributes to both antidepressant efficacy and adverse effects including muscarinic, alpha-1, and monoamine reuptake inhibitory activity; monitoring both compounds is necessary because the combined concentration (target approximately 100 to 300 ng/mL for the amitriptyline-plus-nortriptyline pair) reflects total pharmacological exposure, and because CYP2D6 inhibition or polymorphism affects both compounds simultaneously
• D) The second compound is desipramine, produced when amitriptyline undergoes spontaneous non-enzymatic N-demethylation in plasma at physiological pH; monitoring both is necessary because desipramine's preferential NET selectivity produces a norepinephrine reuptake inhibitory component that is clinically dissociable from amitriptyline's serotonergic component and requires separate dose titration
• E) The second compound is 10-hydroxynortriptyline, a CYP2D6-mediated hydroxylation product of amitriptyline with enhanced blood-brain barrier penetration compared to the parent drug; monitoring both is necessary because 10-hydroxynortriptyline selectively accumulates in patients with renal impairment and is responsible for the CNS toxicity seen in patients with diabetic nephropathy at otherwise standard amitriptyline doses

6. [CASE 2 — QUESTION 2] Continuing with the same patient. Her psychiatrist adds paroxetine 20 mg daily for a recurrent episode of panic disorder. Six weeks later she calls the clinic reporting confusion, palpitations, urinary difficulty, and severe dry mouth. A repeat level shows amitriptyline 304 ng/mL and nortriptyline 198 ng/mL, combined 502 ng/mL -- more than double the prior combined level. The dose of amitriptyline has not been changed. Which of the following correctly identifies the mechanism of the level rise and the appropriate immediate management?

• A) The level rise reflects paroxetine's potent CYP2D6 inhibition reducing the metabolic clearance of both amitriptyline and nortriptyline; at a combined level of 502 ng/mL with symptomatic anticholinergic toxicity, the amitriptyline dose must be reduced -- not paroxetine necessarily discontinued -- and the combined level rechecked at steady state approximately two weeks after the dose change; if the combination is to be continued, plasma level monitoring at each paroxetine dose adjustment is mandatory
• B) The level rise reflects paroxetine's direct displacement of amitriptyline and nortriptyline from alpha-1-acid glycoprotein binding sites, increasing the free (unbound) fraction and causing measured total plasma concentrations to rise without any change in total body drug content; the management is to switch to a protein-binding-sparing antidepressant because protein displacement interactions cannot be managed by dose adjustment
• C) The level rise reflects paroxetine-induced CYP3A4 inhibition, the primary metabolizing enzyme for the amitriptyline-to-nortriptyline conversion pathway; the correct management is to reduce the paroxetine dose rather than adjust amitriptyline, because reducing the inhibitor to a sub-inhibitory concentration will restore normal CYP3A4 activity within 48 hours
• D) The level rise reflects a pharmacodynamic interaction in which paroxetine's SERT inhibition sensitizes SERT to competitive inhibition by amitriptyline and nortriptyline, causing both TCA molecules to bind SERT more avidly and thereby accumulate in serotonergic synapses rather than distributing to peripheral tissues; the apparent plasma level elevation reflects reduced distribution volume rather than reduced clearance
• E) The level rise reflects the pharmacokinetic phenomenon of flip-flop kinetics: paroxetine slows amitriptyline absorption from the gastrointestinal tract by raising gastric pH, creating a prolonged absorption phase that produces sustained plasma concentrations exceeding steady-state values; the management is to separate the dosing of amitriptyline and paroxetine by at least six hours

7. [CASE 2 — QUESTION 3] Continuing with the same patient. After the amitriptyline dose is reduced and the level rechecked, her psychiatrist reflects on whether amitriptyline was the optimal TCA choice for this patient in the first place. She considers whether the patient would have been better served by nortriptyline as monotherapy from the outset. Which of the following best explains why nortriptyline has a preferred clinical position among the TCAs and how its pharmacological profile would have differed from amitriptyline for this specific patient?

• A) Nortriptyline is preferred because it is metabolized by CYP3A4 rather than CYP2D6, making it immune to the paroxetine interaction that caused toxicity in this case; its receptor binding profile is identical to amitriptyline because both are tricyclic compounds with the same dibenzocycloheptene ring structure
• B) Nortriptyline is preferred because it selectively inhibits only the norepinephrine transporter (NET) with no serotonin transporter activity, making it the rational choice when noradrenergic enhancement for neuropathic pain is the primary goal; its complete absence of muscarinic and alpha-1 receptor binding makes it free of anticholinergic and orthostatic adverse effects
• C) Nortriptyline is preferred because it undergoes glucuronidation rather than CYP2D6-mediated metabolism, bypassing the CYP2D6 drug interaction pathway entirely; its therapeutic window is defined by a linear (dose-proportional) concentration-response relationship that makes dosing straightforward without the need for plasma level monitoring
• D) Nortriptyline is preferred because its tertiary amine structure provides more potent SERT and NET inhibition than amitriptyline's secondary amine structure, delivering superior antidepressant and analgesic efficacy at lower plasma concentrations; the reduced dose requirement offsets the higher per-milligram adverse effect burden
• E) Nortriptyline is preferred over amitriptyline because as a secondary amine it has substantially lower muscarinic anticholinergic and alpha-1 adrenergic receptor binding potency than amitriptyline (a tertiary amine), producing less orthostatic hypotension, less urinary retention risk, and less anticholinergic confusion -- all particularly relevant for a 58-year-old with diabetes; it also has the best-characterized therapeutic plasma concentration window (50 to 150 ng/mL as monotherapy) with a curvilinear concentration-response relationship that makes plasma level-guided dosing maximally informative

8. [CASE 2 — QUESTION 4] Continuing with the same patient. After the paroxetine-amitriptyline interaction is managed, the psychiatrist discusses the case with a colleague who raises a different pharmacogenomic scenario: "What if the original supratherapeutic level before paroxetine was added had been discovered in a different patient who was not on any interacting medications? How would you distinguish CYP2D6 poor metabolizer status from an occult drug interaction as the cause?" The psychiatrist explains the clinical and pharmacokinetic features that distinguish the two scenarios. Which of the following correctly contrasts CYP2D6 poor metabolizer (PM) status with ultra-rapid metabolizer (UM) status in the context of TCA therapy, and identifies when CYP2D6 genotyping is clinically indicated?

• A) CYP2D6 poor metabolizers have increased CYP2D6 enzymatic activity and produce lower TCA plasma concentrations than expected at standard doses, often failing to reach therapeutic levels; ultra-rapid metabolizers accumulate TCA at standard doses due to reduced clearance and are at greatest risk for concentration-dependent toxicity; genotyping is indicated when a patient shows unexpected efficacy at sub-therapeutic doses
• B) CYP2D6 poor metabolizers have absent or markedly reduced CYP2D6 activity and accumulate TCA at standard doses due to substantially impaired clearance, reaching supratherapeutic plasma concentrations and experiencing concentration-dependent toxicity; ultra-rapid metabolizers have increased CYP2D6 copies and clear TCA faster than normal, often failing to achieve therapeutic plasma concentrations at standard doses and presenting with treatment failure; genotyping is indicated when unexpected TCA toxicity or treatment failure occurs without an identifiable drug interaction
• C) CYP2D6 poor metabolizers and ultra-rapid metabolizers produce identical TCA plasma concentrations because CYP2D6 activity affects only the tertiary-to-secondary amine conversion rate, not total drug clearance; genotyping is useful only to predict which patients will accumulate active metabolite (nortriptyline) disproportionately and therefore benefit from the metabolite's more favorable receptor binding profile
• D) CYP2D6 poor metabolizers fail to convert amitriptyline to nortriptyline, producing therapeutic benefit from amitriptyline alone at standard doses without any active metabolite contribution; ultra-rapid metabolizers convert amitriptyline to nortriptyline so rapidly that plasma amitriptyline is undetectable and all pharmacological activity derives from nortriptyline; genotyping identifies which metabolite fraction to monitor but does not affect dosing decisions
• E) CYP2D6 pharmacogenomics affects only the ratio of amitriptyline to nortriptyline in plasma, not total combined pharmacological exposure; poor metabolizers have high amitriptyline-to-nortriptyline ratios and ultra-rapid metabolizers have low ratios; genotyping is indicated only when the ratio deviates from the expected 60:40 amitriptyline-to-nortriptyline split at steady state because this deviation predicts an atypical adverse effect profile

9. [CASE 3 — QUESTION 1] A 47-year-old man with treatment-resistant atypical depression has been well-controlled on phenelzine 45 mg daily for eight months. He attends a work dinner and consumes a cheese platter including aged Gruyere and Stilton, charcuterie, and two glasses of Chianti. Approximately 50 minutes after the meal he develops a sudden, explosive headache described as "the worst of my life," accompanied by profuse diaphoresis, facial flushing, nausea, and a sense of impending doom. His partner, a nurse, measures his blood pressure at 236/130 mmHg. He is brought to the emergency department by ambulance. On arrival his blood pressure is 228/126 mmHg and heart rate is 108 bpm. Which of the following correctly identifies the complete pharmacological mechanism producing this presentation and explains why this constitutes a medical emergency?

• A) This presentation reflects serotonin syndrome triggered by tyramine's conversion to tryptamine in the gut when MAO-A is inhibited; tryptamine is a serotonin receptor agonist that floods 5-HT2A receptors in the brainstem vasomotor center, producing central sympathetic activation; the "worst headache of life" pattern reflects serotonin-mediated cerebrovascular vasospasm rather than true hypertension
• B) This presentation reflects a direct pharmacodynamic interaction between phenelzine and the tannins in Chianti wine; wine tannins inhibit catechol-O-methyltransferase (COMT) in the adrenal medulla, preventing catecholamine catabolism and causing epinephrine accumulation; the hypertensive crisis reflects adrenomedullary rather than sympathetic nerve terminal norepinephrine excess
• C) This presentation reflects phenelzine's inhibition of MAO-B selectively; aged cheese and fermented meats contain high concentrations of phenylethylamine (PEA), which is normally catabolized by MAO-B; PEA acts as a direct beta-adrenergic agonist producing tachycardia and is converted to tyramine in peripheral tissues, which then triggers the hypertensive response
• D) This presentation reflects the tyramine pressor response: phenelzine has irreversibly inhibited MAO-A in the intestinal mucosa and liver, abolishing first-pass tyramine extraction; dietary tyramine from the aged cheeses and cured meats entered the systemic circulation intact, was transported into peripheral adrenergic nerve terminals by the norepinephrine transporter, displaced stored norepinephrine in massive quantities, and produced acute severe hypertension through alpha-1 receptor activation; blood pressure of 228/126 mmHg carries immediate risk of intracerebral hemorrhage, hypertensive encephalopathy, and aortic dissection
• E) This presentation reflects accumulation of dietary dopamine from the aged cheeses; MAO-A inhibition by phenelzine prevents hepatic first-pass dopamine catabolism, allowing intact dietary dopamine to reach the systemic circulation where it acts on dopamine D1 receptors in the renal vasculature; the sudden severe headache reflects dopamine-mediated renal vasoconstriction causing acute hypertensive nephropathy with cerebrovascular consequences

10. [CASE 3 — QUESTION 2] Continuing with the same patient. The emergency physician confirms the diagnosis of tyramine-induced hypertensive crisis and initiates treatment. A medical student on the team asks which antihypertensive agent is pharmacologically most appropriate for this specific type of hypertensive crisis, and whether any antihypertensive classes should be avoided. Which of the following correctly identifies the preferred agent class, the pharmacological rationale for its selection, and an agent or class that should be avoided?

• A) Intravenous labetalol is the preferred agent because its combined alpha-1 and non-selective beta-adrenergic blockade addresses the sympathetic excess from all mechanisms simultaneously; pure alpha-1 blockers should be avoided because blocking alpha-1 receptors without blocking beta receptors allows unopposed beta-adrenergic stimulation, converting the hypertensive crisis into a tachyarrhythmia
• B) Intravenous phentolamine (a non-selective alpha-adrenergic blocker) is pharmacologically rational as a primary agent because the hypertension is driven by massive norepinephrine release acting on alpha-1 receptors at peripheral resistance vessels; alternatively, intravenous nicardipine or labetalol can be used; intravenous clonidine should be avoided because it is a centrally acting alpha-2 agonist that reduces sympathetic outflow from the CNS but cannot rapidly reverse the peripheral receptor activation already occurring from the norepinephrine already released
• C) Intravenous enalaprilat (an ACE inhibitor) is the preferred agent because hypertension from norepinephrine excess activates the renin-angiotensin system as a downstream amplifier; blocking angiotensin II formation removes the primary amplification pathway; beta-blockers should be avoided because beta-1 blockade in the setting of massively elevated norepinephrine produces unopposed alpha-1 activation
• D) Intravenous nitroprusside is the only appropriate agent because tyramine-induced hypertensive crisis requires immediate arterial vasodilation through a direct nitric oxide donor mechanism; all adrenergic-blocking agents should be avoided because they interfere with phenelzine's MAO inhibitory effect and can paradoxically worsen norepinephrine accumulation
• E) Intravenous hydralazine is the preferred agent because its direct arteriolar vasodilation bypasses the adrenergic receptor system entirely and avoids any pharmacodynamic interaction with phenelzine; calcium channel blockers should be avoided because their negative chronotropic effects combined with phenelzine's tachycardia from norepinephrine excess create competing chronotropic mechanisms that can produce dangerous heart rate instability

11. [CASE 3 — QUESTION 3] Continuing with the same patient. The hypertensive crisis is successfully managed and the patient is medically stabilized. His psychiatrist visits him in the hospital and conducts a detailed dietary counseling session, emphasizing where the patient's dietary choices went wrong and providing guidance on what he can and cannot eat safely while continuing phenelzine. The patient asks: "Is all cheese forbidden, or just certain kinds?" and "Why does the tyramine content vary so much between different cheeses?" Which of the following correctly answers both questions and identifies the general principle governing tyramine content across food categories?

• A) All cheese is forbidden with irreversible MAOIs because the pasteurization process used in commercial cheese production is insufficient to eliminate tyramine that was formed before pasteurization; the tyramine content does not vary between cheese types because all dairy products contain the same baseline concentration of tyrosine, which is converted to tyramine at a fixed stoichiometric rate regardless of fermentation conditions
• B) Only yellow-colored cheeses are forbidden because tyramine formation requires the cheese-coloring bacterial species Brevibacterium linens; white cheeses such as ricotta and mozzarella use a different bacterial culture that produces histamine rather than tyramine; the variation in tyramine content reflects variation in Brevibacterium density across cheese types
• C) Aged and ripened cheeses -- including cheddar, Stilton, Gruyere, Brie, Camembert, and blue cheeses -- must be strictly avoided because bacterial fermentation during the aging process decarboxylates tyrosine to tyramine, and tyramine content increases with fermentation time and bacterial load; fresh cheeses including cottage cheese, ricotta, and cream cheese are generally safe because they have not undergone significant bacterial fermentation and contain negligible tyramine; the tyramine content of any given food is not fixed by category alone -- the same cheese type can have widely varying tyramine content depending on production conditions, fermentation time, and bacterial colonization
• D) Processed cheeses such as American cheese slices are the highest-risk category because the processing step concentrates tyramine from multiple cheese sources; natural fresh cheeses such as mozzarella carry moderate risk because hand-stretching during production releases tyramine from casein; aged cheeses are paradoxically safer because prolonged aging allows tyramine to oxidize to dopaquinone, which has no sympathomimetic activity
• E) All natural cheeses are equally restricted because tyramine in cheese derives from dietary tyrosine in the consumer's bloodstream that diffuses into the cheese during the aging process; the variation in tyramine content between cheese types reflects variation in the tyrosine content of the milk source rather than bacterial activity; pasteurized cheeses are therefore not safer than unpasteurized cheeses because pasteurization does not affect the tyrosine substrate

12. [CASE 3 — QUESTION 4] Continuing with the same patient. After discharge, the patient tells his psychiatrist that he is considering stopping phenelzine because of the terrifying experience. His psychiatrist acknowledges the seriousness of the event but explains why phenelzine remains a rational choice for this patient despite the dietary interaction risk, provided adherence to dietary restrictions can be assured. The patient had previously failed four antidepressant trials (two SSRIs, one SNRI, one TCA) and meets full criteria for atypical depression with mood reactivity, hypersomnia, hyperphagia, leaden paralysis, and rejection sensitivity. Which of the following best represents the evidence-based argument the psychiatrist should make for continuing phenelzine in this specific patient?

• A) MAOIs, including phenelzine, have demonstrated superiority over both TCAs and placebo in randomized controlled trials specifically designed for the atypical depression subtype defined by mood reactivity, hypersomnia, hyperphagia, leaden paralysis, and rejection sensitivity; for a patient who has failed four prior antidepressant trials across multiple classes and meets the full atypical depression phenotype, phenelzine represents the treatment with the strongest subtype-specific evidence base; the dietary interaction risk is real but manageable with adherence to restrictions, and the prior crisis resulted from non-adherence -- not from an inherent uncontrollable risk -- making continued treatment with improved dietary education a rational choice
• B) MAOIs should be continued because they are the only antidepressants with FDA approval specifically for atypical depression; all other antidepressant classes including SSRIs, SNRIs, and TCAs lack any regulatory indication for atypical depression and therefore cannot be considered evidence-based alternatives for this patient
• C) Phenelzine should be continued because the tyramine interaction risk is statistically negligible; population-level data from MAOI prescriptions show a tyramine crisis rate of less than one per 10,000 patient-years, making the absolute risk lower than the annual mortality risk from untreated major depressive disorder; no dietary modification is actually necessary because modern food processing standards have reduced tyramine content in commercially available foods below the threshold for pressor response
• D) Phenelzine should be continued because stopping it now would cause a two-week period of unprotected serotonergic vulnerability from MAO enzyme resynthesis during which any dietary tyramine exposure would produce a worse pressor response than occurred during active phenelzine treatment; the washout period itself carries higher interaction risk than continued treatment
• E) The psychiatrist should agree to discontinue phenelzine and transition to moclobemide, which has equivalent evidence to phenelzine in atypical depression with a substantially safer dietary interaction profile; moclobemide's reversible MAO-A inhibition and the competitive displacement mechanism eliminate the dietary tyramine risk entirely, making it a strictly superior choice for all patients who have experienced a tyramine crisis on an irreversible MAOI

13. [CASE 4 — QUESTION 1] A 39-year-old woman with treatment-resistant depression has been on phenelzine 45 mg daily for 14 months with good response, but her insurance carrier has declined further coverage of phenelzine and she must transition to a formulary antidepressant. Her psychiatrist chooses venlafaxine. He instructs her to take her last phenelzine dose today and schedules her to start venlafaxine 75 mg daily in two weeks. A pharmacy student doing a rotation asks the attending why the washout is two weeks when phenelzine's plasma half-life is only approximately two hours -- the drug should be pharmacokinetically cleared within 24 hours. Which of the following correctly explains the two-week washout requirement?

• A) The two-week washout is required because phenelzine's plasma half-life is actually 14 days, not two hours; the two-hour value reflects only the initial distribution phase; the true elimination half-life governing washout is the terminal phase half-life during which drug slowly leaches from the CNS lipid compartment back into plasma
• B) The two-week washout is required because phenelzine is an irreversible inhibitor of MAO; it forms a covalent bond with the FAD cofactor of monoamine oxidase, permanently inactivating the enzyme; recovery of MAO activity depends entirely on synthesis of new enzyme protein -- transcription, translation, and membrane incorporation -- which takes approximately two weeks; the pharmacodynamic effect persists long after phenelzine has been eliminated from plasma because enzyme function cannot be restored without new enzyme synthesis
• C) The two-week washout is required because phenelzine irreversibly inhibits monoamine oxidase by forming a covalent bond with the enzyme's FAD cofactor, permanently inactivating it; since MAO cannot be reactivated by any pharmacological means once inactivated, recovery of adequate MAO activity to safely metabolize serotonin requires approximately two weeks for new MAO enzyme protein to be synthesized; phenelzine's short plasma half-life is clinically irrelevant to the washout calculation because the duration of pharmacodynamic effect is governed by enzyme resynthesis kinetics, not plasma drug concentration
• D) The two-week washout is required because venlafaxine has a plasma half-life of 14 days and takes two weeks to reach steady state; starting venlafaxine before it reaches steady state while residual phenelzine is present creates a concentration-dependent interaction window during the venlafaxine titration phase; once venlafaxine reaches steady state the serotonin syndrome risk resolves regardless of phenelzine status
• E) The two-week washout is a conservative regulatory requirement based on post-marketing pharmacovigilance data rather than a pharmacodynamic calculation; the actual MAO recovery time is four to five days in most patients, and the additional nine to ten days represent a population-level safety margin adopted to account for outliers; individual patients with confirmed CYP2D6 extensive metabolizer status can safely start venlafaxine after seven days

14. [CASE 4 — QUESTION 2] Continuing with the same patient. Two years later, venlafaxine has provided only partial response and the patient and her psychiatrist decide to retry phenelzine. She has been on venlafaxine 225 mg daily for the past 18 months. The psychiatrist explains that a washout interval is required after stopping venlafaxine before phenelzine can be started, and that this washout is calculated differently from the previous two-week washout after stopping phenelzine. Which of the following correctly identifies the required washout after stopping venlafaxine before starting phenelzine, and explains why the calculation method differs from the phenelzine-to-venlafaxine direction?

• A) The washout after stopping venlafaxine before starting phenelzine is approximately one week, determined by plasma pharmacokinetics: venlafaxine has a half-life of approximately five hours and its active metabolite desvenlafaxine has a half-life of approximately eleven hours; five half-lives of desvenlafaxine clears the drug to sub-pharmacological concentrations in approximately two to three days, and the clinical washout convention is approximately one week; this is shorter than the phenelzine-to-venlafaxine washout because the determinant in this direction is pharmacokinetic clearance of the serotonergic drug, not enzyme resynthesis -- once venlafaxine and desvenlafaxine are cleared, MAO-A can immediately catabolize serotonin normally
• B) The washout after stopping venlafaxine before starting phenelzine is five weeks, determined by the time for venlafaxine's active metabolite desvenlafaxine to be cleared; desvenlafaxine has a plasma half-life of approximately seven days, making it pharmacokinetically equivalent to norfluoxetine from fluoxetine; five half-lives of desvenlafaxine corresponds to approximately five weeks, the same washout required after fluoxetine
• C) The washout after stopping venlafaxine before starting phenelzine is two weeks -- identical to the washout in the reverse direction -- because serotonin syndrome risk is symmetric: both SERT inhibition and MAO-A inhibition elevate synaptic serotonin, and the duration of serotonergic vulnerability after stopping either drug is two weeks regardless of which was stopped
• D) The washout after stopping venlafaxine before starting phenelzine is four weeks because venlafaxine's noradrenergic component (NET inhibition) requires separate clearance from its serotonergic component (SERT inhibition); the standard two-week SSRI washout covers SERT recovery, but an additional two weeks is required for NET-mediated noradrenergic sensitization to reverse before MAO inhibition is safe
• E) No washout is required when stopping venlafaxine before starting phenelzine because the interaction risk is unidirectional: venlafaxine's SERT inhibition cannot produce serotonin syndrome in combination with MAO-A inhibition because MAO-A inhibition is the cause of serotonin syndrome and SERT inhibition is only an amplifying factor that is clinically insignificant without a prior established state of MAO-A inhibition

15. [CASE 4 — QUESTION 3] Continuing with the same patient. A colleague asks the prescribing psychiatrist to compare this case to a hypothetical scenario: if the patient had been on fluoxetine 40 mg daily instead of venlafaxine before the MAOI restart, how would the washout interval differ and why? The psychiatrist explains that fluoxetine requires a substantially longer washout before phenelzine than venlafaxine does, and that this is one of the most clinically important pharmacokinetic differences between SSRIs. Which of the following correctly identifies the fluoxetine washout interval, explains the specific pharmacokinetic property that mandates it, and articulates why the same calculation applied to venlafaxine yields a much shorter result?

• A) Fluoxetine would require a two-week washout before phenelzine -- identical to the phenelzine-to-venlafaxine washout -- because all antidepressants that inhibit SERT require the same pre-MAOI washout of two weeks, determined by the time for SERT receptor resynthesis to baseline density after competitive inhibition by any SSRI
• B) Fluoxetine would require a three-week washout because it inhibits CYP2D6, which is also involved in phenelzine metabolism; the additional week beyond the standard two-week interval allows CYP2D6 activity to recover before phenelzine is started, preventing phenelzine accumulation from impaired CYP2D6 clearance
• C) Fluoxetine would require a four-week washout because fluoxetine's own plasma half-life is four days; four weeks represents five half-lives of the parent drug and ensures complete pharmacokinetic clearance; venlafaxine requires only one week because its plasma half-life is five hours and five half-lives clears venlafaxine within approximately one day
• D) Fluoxetine and venlafaxine would require the same washout interval of approximately two weeks because both drugs produce equivalent degrees of SERT occupancy at therapeutic doses; the duration of SERT inhibition after stopping either drug is proportional to receptor occupancy at the time of discontinuation, not to the plasma half-life of the drug or its metabolites
• E) Fluoxetine would require a five-week washout before phenelzine because fluoxetine is metabolized to norfluoxetine, an active SERT inhibitor with a plasma half-life of one to two weeks; five half-lives of norfluoxetine corresponds to approximately five weeks, substantially longer than venlafaxine's washout of approximately one week, which is determined by the much shorter half-life of desvenlafaxine (approximately eleven hours); the difference reflects the enormous difference in active metabolite half-lives between the two drugs -- norfluoxetine one to two weeks versus desvenlafaxine eleven hours

16. [CASE 4 — QUESTION 4] Continuing with the same patient. During the discussion of washout intervals, a colleague mentions moclobemide as an MAOI class agent used in Canada and Europe. She notes that moclobemide has a very different washout profile than phenelzine in both directions -- after stopping moclobemide before a serotonergic drug, and after stopping a serotonergic drug before moclobemide. She asks the psychiatrist to explain why the moclobemide washout differs so dramatically from phenelzine in the same scenario. Which of the following correctly explains the mechanistic basis for moclobemide's much shorter washout intervals in both directions, and identifies one significant regulatory limitation?

• A) Moclobemide has shorter washout intervals because it selectively inhibits MAO-B rather than MAO-A; because MAO-A is uninhibited, serotonin can still be catabolized normally during moclobemide treatment and serotonin syndrome risk is absent; no washout is required in either direction when switching to or from any serotonergic drug while on moclobemide
• B) Moclobemide is a reversible inhibitor of MAO-A (RIMA) rather than an irreversible inhibitor; because its binding to MAO-A is non-covalent and competitive, MAO-A enzymatic activity recovers within approximately 24 hours of stopping moclobemide without requiring new enzyme synthesis; the pre-serotonergic-drug washout after stopping moclobemide is therefore approximately 24 hours (not two weeks) because functional MAO activity is restored rapidly once the drug clears; similarly, after stopping a serotonergic drug before starting moclobemide, the washout depends only on pharmacokinetic clearance of the serotonergic drug to sub-pharmacological concentrations; moclobemide is not FDA-approved in the United States and is available clinically in Canada, Europe, and Australia
• C) Moclobemide has shorter washout intervals because it has a much longer plasma half-life than phenelzine, approximately 14 days; at a steady-state plateau concentration that persists for two weeks after stopping, the drug gradually displaces any newly synthesized MAO from its binding site, allowing a smooth transition without an enzyme-free interval; no washout is required when starting a serotonergic drug after stopping moclobemide because the sustained plasma concentration bridges the transition period
• D) Moclobemide has shorter washout intervals because it is eliminated by renal excretion without hepatic metabolism; the 24-hour washout reflects the time for complete renal clearance rather than enzymatic recovery; phenelzine requires two weeks because it is hepatically metabolized to a long-lived covalent enzyme adduct that circulates and continuously re-inhibits newly synthesized MAO for two weeks after the last dose
• E) Moclobemide and phenelzine have identical washout intervals of two weeks; the claim that moclobemide requires only 24 hours is a marketing misrepresentation; randomized crossover pharmacodynamic studies demonstrate that MAO-A activity after moclobemide discontinuation is indistinguishable from phenelzine in terms of recovery kinetics because both drugs produce equivalent degrees of MAO-A inactivation at therapeutic doses despite the mechanistic difference in binding type

17. [CASE 5 — QUESTION 1] A 52-year-old woman with treatment-resistant depression and a history of difficulty adhering to dietary restrictions is started on selegiline transdermal 6 mg per 24 hours (Emsam). Her psychiatrist explains that at this dose, strict dietary tyramine restrictions are not required, distinguishing it from oral irreversible MAOIs such as phenelzine. She asks her psychiatrist to explain exactly why the patch at this dose is different from phenelzine. Which of the following correctly explains the pharmacological basis for the reduced dietary restriction requirement at the 6 mg per 24 hours transdermal dose?

• A) The transdermal patch delivers selegiline at a rate too slow to achieve systemic MAO inhibition; the antidepressant effect at 6 mg per 24 hours is produced through a non-MAO dopaminergic mechanism, and because MAO is not inhibited, dietary tyramine metabolism is completely preserved; at higher doses MAO inhibition begins but selectivity for MAO-B is maintained at all transdermal doses
• B) Selegiline is converted to an inactive sulfoxide in dermal tissue before reaching systemic circulation; at 6 mg per 24 hours the dermal MAO capacity for this inactivation is not saturated and negligible active drug reaches the systemic circulation; at higher patch doses the dermal inactivation pathway is saturated and active selegiline reaches the systemic circulation in quantities sufficient to inhibit gut MAO-A
• C) The transdermal route delivers selegiline directly into portal circulation through dermal capillaries that drain into the portal vein; at 6 mg per 24 hours the drug reaches the gut MAO-A directly and selectively inhibits gut-level tyramine catabolism while sparing hepatic MAO-A; at higher doses hepatic MAO-A is also inhibited through systemic distribution
• D) The transdermal route delivers selegiline into the systemic circulation while largely bypassing first-pass exposure of the gut and liver to high drug concentrations; at 6 mg per 24 hours, gut and hepatic MAO-A -- the critical first-pass barrier that metabolizes dietary tyramine during its portal transit -- remain substantially intact; dietary tyramine continues to be extracted during gut and liver passage and does not reach adrenergic nerve terminals in dangerous quantities; at higher transdermal doses systemic selegiline concentrations become sufficient to inhibit MAO-A at peripheral sympathetic nerve terminals throughout the body, and dietary restriction is then required
• E) The 6 mg transdermal dose maintains complete MAO-B selectivity at all body compartments including peripheral sympathetic nerve terminals; because tyramine pressor response requires MAO-A inhibition at the nerve terminal level and not merely first-pass impairment, MAO-B-selective inhibition at any dose produces no tyramine risk; dietary restriction at 9 and 12 mg doses is required only because those doses produce amphetamine metabolites in quantities sufficient to mimic tyramine's indirect sympathomimetic effect

18. [CASE 5 — QUESTION 2] Continuing with the same patient. After three months at 6 mg per 24 hours with partial response, the psychiatrist increases the patch dose to 9 mg per 24 hours. He calls the patient to inform her of the change and advises her that dietary tyramine restrictions are now required at this higher dose -- the same restrictions required with oral irreversible MAOIs. The patient is confused and upset: "I thought this patch was supposed to be different. Why do the rules change just because of a slightly higher dose?" Which of the following correctly explains the pharmacodynamic threshold that has been crossed with the dose increase to 9 mg per 24 hours?

• A) At 9 mg per 24 hours, systemic selegiline concentrations are sufficient to produce meaningful MAO-A inhibition at peripheral sympathetic nerve terminals throughout the body; even if gut and hepatic MAO-A retain some residual activity and partially limit tyramine absorption, the inhibition of terminal-level MAO-A means that any tyramine reaching adrenergic nerve terminals is not degraded after uptake, amplifying norepinephrine displacement and restoring the dietary tyramine pressor response risk; the dose-dependent threshold reflects the systemic drug concentration needed to inhibit MAO-A at the peripheral effector site rather than only at gut/hepatic first-pass sites
• B) At 9 mg per 24 hours, the transdermal delivery rate now exceeds the absorption capacity of dermal vasculature, causing local saturation and spillover of drug into portal-draining lymphatics; this portal delivery route at higher doses directly exposes hepatic MAO-A to high drug concentrations and inhibits the hepatic first-pass tyramine extraction that was preserved at 6 mg per 24 hours
• C) At 9 mg per 24 hours, selegiline's amphetamine metabolites accumulate to concentrations sufficient to act as competitive MAO-A substrates; the amphetamine metabolites competitively displace MAO-A's endogenous substrates including tyramine, paradoxically increasing gut-level tyramine accumulation by reducing the availability of MAO-A for tyramine catabolism even though selegiline itself does not directly inhibit gut MAO-A at any dose
• D) At 9 mg per 24 hours, the transdermal patch releases drug transdermally through sweat gland ducts in addition to passive diffusion through skin lipid; sweat gland delivery deposits drug directly onto gut mucosal surfaces during transit through the GI tract, producing first-pass-equivalent exposure of gut MAO-A to high local drug concentrations
• E) At 9 mg per 24 hours, selegiline's plasma protein binding becomes saturated, causing the free fraction to rise sharply and producing disproportionately higher tissue concentrations including in the intestinal mucosa and liver; the gut and hepatic MAO-A inhibition at this dose threshold reflects free-fraction saturation kinetics rather than a change in the drug's intrinsic MAO-A selectivity or inhibitory potency

19. [CASE 5 — QUESTION 3] Continuing with the same patient. The patient asks whether there is any MAOI-type drug that does not require dietary restrictions at any dose. Her psychiatrist explains that one such agent exists outside the United States, explains why it carries a substantially lower dietary risk, and describes the mechanism by which tyramine itself partially protects against its own pressor response when this drug is used. Which of the following correctly identifies the agent, its mechanism of reduced tyramine risk, and its regulatory status?

• A) Tranylcypromine used at doses below 20 mg daily maintains partial MAO-B selectivity and requires only moderate dietary restriction; at sub-threshold doses tyramine competitively inhibits tranylcypromine's binding to MAO-A through allosteric modulation of the FAD binding site; tranylcypromine is FDA-approved for depression but the low-dose selective protocol is not included in the prescribing information
• B) Rasagiline, used at antidepressant doses of 2 to 4 mg daily, maintains strict MAO-B selectivity at these doses and does not inhibit gut or hepatic MAO-A at any dose; no dietary restriction is required at any rasagiline dose; it is FDA-approved for Parkinson's disease but not for depression, though off-label antidepressant use is supported by clinical evidence
• C) Moclobemide is a reversible inhibitor of MAO-A (RIMA) available in Canada, Europe, and Australia but not FDA-approved in the United States; its reversible, competitive MAO-A inhibition means that when dietary tyramine is ingested in high concentrations, tyramine itself can competitively displace moclobemide from the MAO-A active site, partially restoring enzyme activity and substantially reducing the pressor response; this competitive displacement mechanism makes moclobemide substantially less dangerous with dietary tyramine than irreversible MAOIs, though very high tyramine loads should still be avoided
• D) Phenelzine at low "antidepressant-threshold" doses of 15 mg daily maintains partial reversibility of MAO-A binding because only 60% of MAO-A molecules are covalently inactivated at this dose; tyramine competitively displaces phenelzine from the remaining 40% of reversibly bound MAO-A enzyme, preserving first-pass tyramine extraction at this dose tier; dietary restriction is not required below 30 mg phenelzine daily
• E) Safinamide, an MAO-B inhibitor approved for Parkinson's disease adjunctive therapy, can be used at antidepressant doses with no dietary restrictions; its reversible MAO-B inhibition is displaced by tyramine at the MAO-B active site through a competitive mechanism identical to moclobemide's MAO-A displacement; safinamide is available in the United States and represents a safer alternative to phenelzine for atypical depression

20. [CASE 5 — QUESTION 4] Continuing with the same patient. After 12 months on selegiline transdermal 9 mg per 24 hours with good response, her psychiatrist needs to switch her to an SSRI due to a new insurance formulary change. The patient asks: "Since the patch is different from phenelzine -- it bypasses the gut -- does that mean I need a shorter washout before starting the SSRI compared to what would be needed after phenelzine?" The psychiatrist explains that the washout requirement is the same regardless of how selegiline was delivered. Which of the following correctly explains why the route of delivery does not affect the washout interval?

• A) The washout after selegiline transdermal is shorter than after phenelzine because the transdermal route produces lower peak plasma concentrations, meaning fewer total MAO molecules are inactivated per dose; with fewer inactivated MAO molecules, enzyme resynthesis is completed faster -- approximately one week rather than two -- and the SSRI can be started sooner
• B) The washout after selegiline transdermal is indeed shorter than after phenelzine -- approximately four days rather than two weeks -- because the transdermal route avoids first-pass MAO inhibition in the gut and liver, meaning those gut and hepatic MAO-A molecules were never inactivated and continue functioning throughout selegiline treatment; only the systemic (non-gut) MAO pool requires resynthesis, which proceeds faster
• C) The washout after selegiline transdermal is shorter than after oral selegiline but identical to after phenelzine -- both require two weeks -- because both oral selegiline at antidepressant doses and phenelzine inhibit gut and hepatic MAO-A, and gut MAO resynthesis is the rate-limiting step regardless of how the systemic MAO pool was affected
• D) No washout is required after stopping selegiline transdermal before starting an SSRI at any dose because the transdermal route produces only peripheral sympathetic MAO inhibition without any CNS MAO-A inhibition; SSRIs interact with central serotonergic MAO-A only, which was never inhibited by the transdermal route
• E) The washout after stopping selegiline transdermal 9 mg per 24 hours before starting an SSRI is two weeks -- the same as after phenelzine -- because the washout interval is determined by the time for new MAO enzyme synthesis, not by the route of drug delivery; selegiline at antidepressant doses (whether oral or transdermal) irreversibly inhibits MAO by covalent FAD modification throughout the body including in CNS serotonergic neurons, and recovery of adequate MAO activity requires approximately two weeks of enzyme resynthesis regardless of whether the drug was administered transdermally or orally

21. [CASE 6 — QUESTION 1] A 33-year-old woman on tranylcypromine 30 mg twice daily for treatment-resistant depression is brought to the emergency department by her partner. Over the past two hours she has developed progressive agitation, confusion, profuse diaphoresis, and muscle stiffness. Her temperature is 39.8°C, heart rate is 128 bpm, and blood pressure is 148/92 mmHg. Examination reveals hyperreflexia with clonus at the ankles, muscle rigidity predominantly in the lower extremities, and mydriasis. Her partner reports she has been strictly following her dietary restrictions but took two doses of an over-the-counter cold-and-flu preparation six hours ago. The preparation contained dextromethorphan 15 mg and pseudoephedrine 30 mg per dose. Which of the following best identifies the primary drug interaction responsible for this presentation and explains why the clinical picture is more consistent with serotonin syndrome than with a tyramine-type hypertensive crisis?

• A) This presentation reflects a tyramine-type hypertensive crisis from pseudoephedrine acting as an indirect sympathomimetic releasing norepinephrine from adrenergic nerve terminals; the elevated temperature reflects norepinephrine-mediated thermogenesis; the clonus and hyperreflexia reflect reflex motor hyperactivity from hypertension-induced cerebrovascular spasm; the blood pressure of 148/92 mmHg, while elevated, is lower than expected for a tyramine crisis, suggesting partial response to the patient's endogenous baroreceptor reflexes
• B) This presentation is most consistent with serotonin syndrome precipitated primarily by dextromethorphan's serotonin reuptake inhibitory (SERT-blocking) properties combined with tranylcypromine's irreversible MAO-A inhibition; the clinical triad of neuromuscular excitability (clonus, hyperreflexia, rigidity), autonomic instability (tachycardia, diaphoresis, mild hypertension), and altered mental status (agitation, confusion) is characteristic of serotonin syndrome rather than tyramine crisis; tyramine crisis produces predominantly severe hypertension with explosive headache and noradrenergic features without the neuromuscular excitability pattern
• C) This presentation reflects combined serotonin syndrome and tyramine crisis occurring simultaneously from two separate interactions -- dextromethorphan triggering serotonin syndrome and pseudoephedrine triggering tyramine crisis -- and both interactions require treatment simultaneously; the two syndromes cannot be distinguished clinically and require treatment for both pathways in parallel
• D) This presentation reflects opioid receptor activation from dextromethorphan at high doses; at two doses of 15 mg, dextromethorphan has achieved sufficient plasma concentrations to activate mu-opioid receptors in the brainstem, producing a centrally mediated autonomic storm; the muscle rigidity reflects opioid-induced chest wall rigidity; tranylcypromine contributed by inhibiting dextromethorphan's CYP2D6-mediated first-pass metabolism, causing dextromethorphan accumulation
• E) This presentation reflects NMDA receptor blockade by dextromethorphan compounded by tranylcypromine's norepinephrine-enhancing effects; the clinical picture represents a dissociative-sympathomimetic syndrome rather than serotonin syndrome; treatment with an NMDA receptor antagonist is contraindicated because it would compound the dextromethorphan-mediated blockade

22. [CASE 6 — QUESTION 2] Continuing with the same patient. The emergency physician treating the patient confirms the diagnosis of serotonin syndrome and initiates management. A clinical pharmacology fellow is asked to explain to the emergency team why the pseudoephedrine component of the cold preparation poses a separate and distinct danger in this patient -- specifically why it carries its own interaction risk with tranylcypromine even though it is not primarily a serotonergic drug. Which of the following correctly explains pseudoephedrine's specific mechanism of interaction with MAOIs and why this interaction is pharmacologically distinct from the dextromethorphan-MAOI interaction?

• A) Pseudoephedrine is a direct MAO-A substrate that accumulates when MAO-A is inhibited by tranylcypromine; accumulated pseudoephedrine then acts directly on alpha-1 and beta-1 adrenergic receptors, producing the combined vasopressor and cardiac stimulatory effects of a full adrenergic agonist; this mechanism is pharmacologically distinct from the dextromethorphan interaction because pseudoephedrine directly activates adrenergic receptors while dextromethorphan acts on serotonin receptors
• B) Pseudoephedrine inhibits catechol-O-methyltransferase (COMT) at peripheral sympathetic terminals, preventing norepinephrine catabolism by the COMT pathway; combined MAO-A inhibition and COMT inhibition eliminates both intraneuronal norepinephrine degradation pathways simultaneously, producing supraphysiological norepinephrine levels at the synapse; this interaction is distinct from the dextromethorphan mechanism because it targets catecholamine catabolism rather than serotonin metabolism
• C) Pseudoephedrine is a selective MAO-B substrate; when tranylcypromine inhibits MAO-B, pseudoephedrine is converted to phenylethylamine (PEA) rather than being deaminated; PEA accumulates and acts as a potent indirect dopaminergic agent, producing dysphoria and cardiovascular stimulation; this mechanism is distinct from dextromethorphan because PEA acts on dopamine pathways rather than serotonin pathways
• D) Pseudoephedrine is an indirect sympathomimetic that is transported into adrenergic nerve terminals by the norepinephrine transporter (NET) and displaces stored norepinephrine from vesicles, causing norepinephrine release; when MAO-A (and MAO-B) are irreversibly inhibited by tranylcypromine, norepinephrine stores in adrenergic nerve terminals are augmented because intraneuronal norepinephrine is not catabolized between release events; pseudoephedrine acting on these enlarged norepinephrine stores displaces a disproportionately large norepinephrine load, risking a hypertensive crisis; this mechanism is pharmacologically distinct from the dextromethorphan interaction because it operates through norepinephrine displacement (noradrenergic) rather than serotonin reuptake inhibition (serotonergic)
• E) Pseudoephedrine directly activates presynaptic trace amine-associated receptor 1 (TAAR1) at adrenergic nerve terminals, triggering Gs-protein-coupled vesicular norepinephrine release through a mechanism independent of the norepinephrine transporter; MAO inhibition amplifies this effect by preventing reuptaken norepinephrine from being catabolized after re-entry; the distinction from dextromethorphan is that TAAR1 activation is a receptor-mediated mechanism while dextromethorphan's effect is transporter-mediated

23. [CASE 6 — QUESTION 3] Continuing with the same patient. The emergency physician asks the pharmacology fellow to outline the treatment approach for serotonin syndrome and to explain how it differs from the treatment approach for a tyramine-induced hypertensive crisis in an MAOI patient. Which of the following correctly contrasts the management priorities for each syndrome?

• A) Serotonin syndrome treatment focuses on removing the serotonergic precipitant, providing supportive care, administering benzodiazepines for neuromuscular excitability and agitation, and considering cyproheptadine (a non-selective serotonin receptor antagonist) to competitively block serotonin at 5-HT1A and 5-HT2A receptors; tyramine-induced hypertensive crisis treatment focuses on parenteral antihypertensive therapy targeting the alpha-1-mediated vasoconstriction, with phentolamine, nicardipine, or labetalol as appropriate agents; the two syndromes differ in the effector mechanism (serotonin receptor excess vs. alpha-1 adrenergic receptor activation by released norepinephrine) and therefore require pharmacologically distinct treatment targets
• B) Serotonin syndrome and tyramine crisis are both treated with intravenous phentolamine as the primary agent because phentolamine's non-selective adrenergic blockade addresses both the noradrenergic component of serotonin syndrome and the alpha-1 activation of tyramine crisis; cyproheptadine is added for serotonin syndrome only as a second-line agent once phentolamine has stabilized the cardiovascular component
• C) Serotonin syndrome is treated with a MAO-A activator to restore serotonin catabolism; because no MAO-A activator is clinically available, treatment is supportive with high-dose activated charcoal to bind free serotonin in the gastrointestinal tract; tyramine crisis is treated identically because both represent monoamine excess syndromes that respond to the same gastrointestinal decontamination strategy
• D) Serotonin syndrome is treated with intravenous naloxone, which blocks the mu-opioid receptors through which dextromethorphan (an opioid-like compound) produces serotonin excess; tyramine crisis is treated with intravenous atropine to block the muscarinic receptors responsible for the vasodilatory component of the norepinephrine-mediated hypertension; the two treatments are complementary and are given simultaneously when both syndromes are present
• E) Both syndromes are treated with cessation of the offending drug and intravenous lorazepam; specific antidotes are not available or indicated for either condition; phentolamine is avoided in both syndromes because its alpha-adrenergic blockade would produce unopposed beta-adrenergic stimulation and worsen the tachycardia common to both presentations

24. [CASE 6 — QUESTION 4] Continuing with the same patient. The patient recovers and is discharged. Before discharge, her psychiatrist conducts a counseling session about over-the-counter medications she must avoid while on tranylcypromine, and identifies which ingredients are dangerous versus which OTC cold symptom treatments are safer alternatives. Which of the following correctly identifies the contraindicated OTC ingredient categories, their mechanisms of interaction with MAOIs, and a safer symptomatic alternative for nasal congestion?

• A) All OTC medications must be avoided entirely with irreversible MAOIs; there are no safe OTC alternatives for any symptom category; patients on MAOIs must see their physician for a prescription for any symptomatic treatment including nasal congestion, cough, and fever; acetaminophen cannot be used because MAO inhibition prevents its hepatic glucuronidation, causing toxic acetaminophen accumulation
• B) Antihistamines (first-generation) must be avoided because they are potent indirect sympathomimetics that displace norepinephrine from adrenergic terminals; decongestants such as pseudoephedrine are safe because their mechanism of action is direct alpha-1 agonism that does not interact with MAO-inhibited terminals; plain acetaminophen and guaifenesin are safe for fever and congestion respectively
• C) Sympathomimetic decongestants including pseudoephedrine and phenylephrine must be avoided because they are indirect sympathomimetics (or have indirect sympathomimetic properties) that risk norepinephrine displacement from MAO-inhibited nerve terminals with enlarged norepinephrine stores, risking hypertensive crisis; dextromethorphan must be avoided because its SERT inhibitory properties combined with MAO-A inhibition risk serotonin syndrome; safer alternatives for nasal congestion include intranasal saline irrigation and topical (intranasal) oxymetazoline used cautiously for short periods -- since topical decongestants have minimal systemic absorption, they carry substantially less interaction risk than oral sympathomimetics; plain acetaminophen is safe for fever and pain
• D) Dextromethorphan-containing cough suppressants are safe because tranylcypromine selectively inhibits MAO-B and dextromethorphan is a MAO-A substrate that is catabolized normally; pseudoephedrine must be avoided because it is a direct MAO-A substrate that accumulates when MAO-A is inhibited; intranasal corticosteroids are contraindicated because they upregulate MAO-A expression and reverse the antidepressant effect of tranylcypromine
• E) Only products containing tyramine must be avoided; dextromethorphan and pseudoephedrine are safe because neither is tyramine and neither acts through the tyramine mechanism; the dietary restriction to avoid aged cheeses and fermented foods does not extend to pharmacologically active drug ingredients because drugs are metabolized by CYP enzymes rather than by MAO